PTK2 and mesothelioma: In patients with mesothelioma or solid tumors, combination treatment with GSK2256098 and trametinib, a MEK inhibitor, demonstrated that 38% (13/34) of patients presented SD and 50% (3/6) patients demonstrated more than a 70% decrease in phosphorylated FAK/FAK (ClinicalTrials.gov Identifier: NCT01938443) (Mak et al., 2019).